Sign inJoin waitlistJoin the waitlist

Fahed Bitar

Physician · Foothill Cardiology Medical Group Inc

Credentials: · · · · ·

History

Foothill Cardiology Medical Group Inc
Present

Keck School of Medicine of USC
2006–2007
St. Elizabeth Hospital of Boston
2005–2006
Icahn School of Medicine at Mount Sinai
2002–2005
Internal Medicine
University of Southern California/Los Angeles General Medical Center
1999–2002
Ross University School of Medicine
1995–1999

Research

Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation
Circulation · 2005 · 359 citations
Clinical profile and predictors of complications in peripartum cardiomyopathy
Journal of Cardiac Failure · 2009 · 209 citations
Valvular heart disease and pregnancy: part II: prosthetic valves
Review · Journal of the American College of Cardiology · 2005 · 150 citations

Uri Elkayam
11 papers
Mohammed Akhter
6 papers · 6 as a fellow
AH
Afshan Hameed
2 papers · 2 as a fellow
Kalgi Modi
2 papers
MJ
Munir Janmohamed
2 papers · 2 as a fellow
PH
Parta Hatamizadeh
2 papers
AC
Adib Chaaya
1 paper
AL
Amir Lerman
1 paper
AB
Andrew Burger
1 paper
AR
Angela Ro
1 paper · 1 as a fellow
AI
Annika Illum
1 paper · 1 as a fellow
Jordan Safirstein
1 paper

Clinical trials

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2026–2027
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Site PI · Recruiting · Phase 4
Duke University
2025–2029
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
Site PI · Recruiting · Phase 2
Novartis Pharmaceuticals
2024–2030